Selinexor (KPT-330) in Older Patients With Relapsed AML
- Conditions
- Interventions
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 317
- Registration Number
- NCT02088541
- Locations
- πΊπΈ
Jonsson Comprehensive Cancer Center / University of California, Los Angeles, Los Angeles, California, United States
π³π±VU University Medical Center, Amsterdam, Netherlands
πΊπΈColorado Blood Cancer Institute/Sarah Cannon Research Institute, Denver, Colorado, United States
Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2014-01-01
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 116
- Registration Number
- NCT02025985
- Locations
- π©π°
Aalborg University Hospital, Aalborg, Denmark
π§πͺUZ Leuven - Universitair Ziekenhuis Leuven, Leuven, Belgium
π©π°Rigshospitalet, Copenhagen, Denmark
Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas
- First Posted Date
- 2013-11-18
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 76
- Registration Number
- NCT01986348
- Locations
- π©π°
The Phase I Unit, Dept. of Oncology, Rigshospitalet, Copenhagen, Denmark
π³π±University of Groningen Faculty of Medical Sciences, Medical Oncology, Groningen, Netherlands
πΊπΈDana Farber Cancer Institute, Center for Neuro-Oncology, Boston, Massachusetts, United States
A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 54
- Registration Number
- NCT01896505
- Locations
- π¨π¦
Princess Margaret Hospital, Toronto, Ontario, Canada
πΊπΈMemorial Sloan Kettering Cancer Centre, New York, New York, United States
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
- First Posted Date
- 2012-05-30
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 286
- Registration Number
- NCT01607892
- Locations
- πΊπΈ
The Ohio State University, Columbus, Ohio, United States
π©π°Rigshospitalet, Copenhagen, Denmark
π¨π¦Tom Baker Cancer Centre, Calgary, Alberta, Canada
Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
- First Posted Date
- 2012-05-30
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 192
- Registration Number
- NCT01607905
- Locations
- π¨π¦
Princess Margaret Hospital, Toronto, Ontario, Canada
πΊπΈGabrail Cancer Center, Canton, Ohio, United States
π©π°Rigshospitalet, Copenhagen, Denmark